273 reports of this reaction
1.9% of all LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS reports
#11 most reported adverse reaction
ASTHENIA is the #11 most commonly reported adverse reaction for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, manufactured by Cipla USA Inc.. There are 273 FDA adverse event reports linking LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS to ASTHENIA. This represents approximately 1.9% of all 14,515 adverse event reports for this drug.
Patients taking LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS who experience asthenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASTHENIA is a less commonly reported adverse event for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, but still significant enough to appear in the safety profile.
In addition to asthenia, the following adverse reactions have been reported for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS:
The following drugs have also been linked to asthenia in FDA adverse event reports:
ASTHENIA has been reported as an adverse event in 273 FDA reports for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASTHENIA accounts for approximately 1.9% of all adverse event reports for LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, making it a notable side effect.
If you experience asthenia while taking LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.